Lebrikizumab provides clinically meaningful response in face and hands in adults and adolescents with moderate-to-severe atopic dermatitis: ADhope 1 study

Einleitung / Background: Most patients with atopic dermatitis (AD) have face and/or hand involvement, which poses a major psychological burden. 1 Lebrikizumab is approved for moderate-to-severe AD and has previously demonstrated efficacy and a favourable safety profile.[2][3][4] We report Lebrikizumab efficacy in face and hands from ADhope 1 (NCT05990725).Methodik / Methods: ADhope 1 was a 24-Week (W), interventional, single-arm, open-label study in adults and adolescents (≥ 12 to < 18 years, ≥ 40 kg) with AD and who were not adequately controlled with topical therapies.Patients received 500 mg at baseline and W2, then 250 mg every 2 weeks (Q2W) until W16, then 250 mg Q4W until W24.Outcomes included Face Investigator's Global Assessment (IGA) ≥ 1-point improvement from baseline and Face IGA 0/1 with ≥ 2-point improvement from baseline in patients with Face IGA ≥ 2 at baseline, and percentage change from baseline in modified Total Lesion Symptom Score (mTLSS) to assess response in hands.Ergebnisse / Results: Efficacy was assessed in 247 patients.Of the 172 patients with Face IGA ≥2 at baseline (69.6%), 79.1% achieved Face IGA ≥ 1-point improvement and 44.8% achieved Face IGA 0/1 with ≥ 2-point improvement at W24. Face response correlated with overall body response.Of patients with AD in the hands at baseline (n = 158), the mean percentage change from baseline in mTLSS progressively improved over time and was -66.3% at W24. Schlussfolgerung / Conclusion: Lebrikizumab provided improvements in AD affecting the face and/or hands.Findings indicate that Lebrikizumab is an effective treatment option for patients with moderate-severe AD, including those with facial and hand involvement.